MAP3K4 Polyclonal antibody
MAP3K4 Polyclonal Antibody for WB, IF/ICC, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human, mouse, rat
Applications
WB, IF/ICC, ELISA
Conjugate
Unconjugated
Cat no : 21610-1-AP
Synonyms
Validation Data Gallery
Tested Applications
Positive WB detected in | K-562 cells |
Positive IF/ICC detected in | Hela cells |
Recommended dilution
Application | Dilution |
---|---|
Western Blot (WB) | WB : 1:1000-1:4000 |
Immunofluorescence (IF)/ICC | IF/ICC : 1:10-1:100 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
Published Applications
IF | See 1 publications below |
Product Information
The immunogen of 21610-1-AP is MAP3K4 Fusion Protein expressed in E. coli.
Tested Reactivity | human, mouse, rat |
Cited Reactivity | human |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Immunogen | MAP3K4 fusion protein Ag16254 |
Full Name | mitogen-activated protein kinase kinase kinase 4 |
Calculated Molecular Weight | 1608 aa, 182 kDa |
Observed Molecular Weight | 170-180 kDa |
GenBank Accession Number | BC146770 |
Gene Symbol | MAP3K4 |
Gene ID (NCBI) | 4216 |
RRID | AB_10804775 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Antigen affinity purification |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Protocols
Product Specific Protocols | |
---|---|
WB protocol for MAP3K4 antibody 21610-1-AP | Download protocol |
IF protocol for MAP3K4 antibody 21610-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
Publications
Species | Application | Title |
---|---|---|
J Gene Med Construction and validation of molecular subtype and signature of immune cell-related telomeric genes and prediction of prognosis and immunotherapy efficacy in ovarian cancer patients |